NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
NEUROCRINE BIOSCIENCES INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $3.35B | $3.08B | $2.83B | $2.66B | $2.48B | $2.39B | $2.33B | $2.22B | $2.09B | $1.95B | $1.86B | $1.76B | 99.4% | +35.0% |
| Collaboration revenues | $20.40M | $21.20M | $26.60M | $25.90M | $26.40M | $27.30M | $24.70M | $26.20M | $27.70M | $27.70M | $26.50M | $25.90M | 0.6% | -22.7% |
By region
From the segment and revenue-disaggregation notes of Neurocrine Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.